Investigation of modulating effect of Qingfei Paidu Decoction on host metabolism and gut microbiome in rats

WU Gao-song1 ZHONG Jing1,2 ZHENG Ning-ning1 WANG Chao-ran3,4 JIN Hong-li3,4 GE Guang-bo1 HAN Jing-yan5 GAO Yue6 SHENG Li-li1 ZHANG Wei-dong1,7 LI Hou-kai1

(1.Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China 201203)
(2.Huzhou Key Laboratory of Molecular Medicine, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China 313000)
(3.Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, Liaoning, China 116023)
(4.Innovation Institute of Medicine, China Medical City, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Taizhou, Jiangsu, China 225316)
(5.Department of Integrated Traditional Chinese and Western Medicine, Peking University Health Science Center, Beijing, China 100191)
(6.Institute of Radiation Medicine, Academy of Military Medical Sciences, Academy of Military Sciences, Beijing, China 100039)
(7.School of Pharmacy, Second Military Medical University, Shanghai, China 200433)

【Abstract】This study is to explore the effect of Qingfei Paidu Decoction (QPD) on the host metabolism and gut microbiome of rats with metabolomics and 16S rDNA sequencing. Based on 16S rDNA sequencing of gut microbiome and metabolomics (GC-MS and LC-MS/MS), we systematically studied the serum metabolite profiles and gut microbiota composition of the rats treated with QPD for continued 5 days by oral gavage. A total of 23 and 43 differential metabolites were identified based on QPD with GC-MS and LC-MS/MS, respectively. The involved metabolic pathways of these differential metabolites included glycerophospholipid metabolism, linoleic acid metabolism, TCA cycle and pyruvate metabolism. Meanwhile, we found that QPD significantly regulated the composition of gut microbiota in rats, such as enriched Romboutsia, Turicibacter, and Clostridium_sensu_stricto_1, and decreased norank_f_Lachnospiraceae. Our current study indicated that short-term intervention of QPD could significantly regulate the host metabolism and gut microbiota composition of rats dose-dependently, suggesting that the clinical efficacy of QPD may be related with the regulation on host metabolism and gut microbiome.

【Keywords】 Qingfei Paidu Decoction; COVID-19; metabolomics; gut microbiome; inflammation; immune;

【DOI】

【Funds】 National Key R&D Program of China (2020YFC0845400, 2017YFC1700200)

Download this article

(Translated by ZHAO B)

    References

    [1] National Administration of Traditional Chinese Medicine. Several traditional Chinese medicines have been initially proved to have obvious curative effect, and the central guiding team requires a timely summary [EB/OL]. (2020-03-05) [2020-06-09]. http://www.satcm.gov.cn/xinxifabu/shizhengyaowen/2020-03-05/13617.html (in Chinese).

    [2] National Administration of Traditional Chinese Medicine. Notice on recommending “Qingfei Paidu Decoction” in the treatment of COVID-19 with integrated Chinese and Western medicines [EB/OL]. (2020-02-07) [2020-06-09]. http://yzs.satcm.gov.cn/zhengcewenjian/2020-02-07/12876.html (in Chinese).

    [3] National Administration of Traditional Chinese Medicine. Progress has been made in the screening for effective prescriptions of traditional Chinese medicine, and clinical observation in pilot provinces has shown more than 90% overall efficacy of treatment with Qingfei Paidu Decoction [EB/OL].(2020-02-06) [2020-06-09]. http://bgs.satcm.gov.cn/gongzuodongtai/2020-02-06/12866.html (in Chinese).

    [4] WU H, WANG J Q, YANG Y W, et al. Preliminary exploration of the mechanism of Qingfei Paidu decoction against novel coronavirus pneumonia based on network pharmacology and molecular docking technology [J]. Acta Pharmaceutica Sinica, 2020, 55 (3): 374 (in Chinese).

    [5] XU T F, HE C G, YANG K. Network pharmacology-based study on material basis and mechanism of Qingfei Paidu Decoction against COVID-19 [J/OL]. Natural Product Research and Development, 2020, http://kns.cnki.net/kcms/detail/51.1335.Q.20200413.1918.018.html (in Chinese).

    [6] ZHAO J, TIAN S S, YANG J, et al. Investigating mechanism of Qing-Fei-Pai-Du-Tang for treatment of COVID-19 by network pharmacology [J]. Chinese Traditional and Herbal Drugs, 2020, 51 (4): 829 (in Chinese).

    [7] ZHOU Y Y, GAO W Y, GU X R, et al. Identification and attribution of chemical constituents of Qingfei Paidu Decoction based on UHPLC-LTQ-Orbitrap-MS technology [J]. China Journal of Chinese Materia Medica, 2020, 45 (13): 3035 (in Chinese).

    [8] NEWGARD C B. Metabolomics and metabolic diseases: where do we stand? [J]. Cell Metab, 2017, 25 (1): 43.

    [9] WU G, ZHANG W, LI H. Application of metabolomics for unveiling the therapeutic role of traditional Chinese medicine in metabolic diseases [J]. J Ethnopharmacol, 2019, 242: 112057.

    [10] RASTELLI M, CANI P D, KNAUF C. The gut microbiome influences host rndocrine functions [J]. Endocr Rev, 2019, 40 (5): 1271.

    [11] HILLS R D, PONTEFRACT B A, MISHCON H R, et al. Gut microbiome: profound implications for diet and disease [J]. Nutrients, 2019, 11 (7): 1613.

    [12] ZHANG R, GAO X, BAI H, et al. Traditional Chinese medicine and gut microbiome: their respective and concert effects on healthcare [J]. Front Pharmacol, 2020, 11: 538.

    [13] ZUO T, ZHANG F, LUI G C Y, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization [J]. Gastroenterology, 2020, doi: 10.1053/j.gastro.2020.05.048.

    [14] YANG T, CHAKRABORTY S, SAHA P, et al. Gnotobiotic rats reveal that gut microbiota regulates colonic mRNA of Ace2, the receptor for SARS-CoV-2 infectivity [J]. Hypertension, 2020, doi: 10.1161/hypertensionaha.120.15360.

    [15] WU G, CHEN L, GU Y, et al. Exploring the mechanism underlying the cardioprotective effect of Shexiangbaoxin Pill on acute myocardial infarction rats by comprehensive metabolomics [J]. J Ethnopharmacol, 2020, 259: 113001.

    [16] SHEN B, YI X, SUN Y, et al. Proteomic and metabolomic characterization of COVID-19 patient sera [J]. Cell, 2020, doi: 10.1016/j.cell.2020.05.032.

    [17] SHINDOU H, HISHIKAWA D, HARAYAMA T, et al. Generation of membrane diversity by lysophospholipid acyltransferases [J]. J Biochem, 2013, 154 (1): 21.

    [18] MAKIDE K, KITAMURA H, SATO Y, et al. Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol [J]. Prostaglandins Other Lipid Mediat, 2009, 89 (3/4): 135.

    [19] SEVASTOU I, KAFFE E, MOURATIS M A, et al. Lysoglycerophospholipids in chronic inflammatory disorders: the PLA(2)/LPC and ATX/LPA axes [J]. Biochim Biophys Acta, 2013, 1831 (1): 42.

    [20] IZQUIERDO E, CUEVAS V D, FERNANDEZ-ARROYO S, et al. Reshaping of human macrophage polarization through modulation of glucose catabolic pathways [J]. J Immunol, 2015, 195 (5): 2442.

    [21] ANGELA M, ENDO Y, ASOU H K, et al. Fatty acid metabolic reprogramming via mTOR-mediated inductions of PPARgamma directs early activation of T cells [J]. Nat Commun, 2016, 7: 13683.

    [22] BORREGAARD N, HERLIN T. Energy metabolism of human neutrophils during phagocytosis [J]. J Clin Invest, 1982, 70 (3): 550.

    [23] POURFATHI M, CEREDA M, CHATTERJEE S, et al. Lung metabolism and inflammation during mechanical ventilation: an imaging approach [J]. Sci Rep, 2018, 8 (1): 3525.

    [24] GASPAR P, AL-BAYATI F A, ANDREW P W, et al. Lactate dehydrogenase is the key enzyme for pneumococcal pyruvate metabolism and pneumococcal survival in blood [J]. Infect Immun, 2014, 82 (12): 5099.

    [25] CALDER P C, ALBERS R, ANTOINE J M, et al. Inflammatory disease processes and interactions with nutrition [J]. Br J Nutr, 2009, 101 (Suppl 1): S1.

    [26] INNES J K, CALDER P C. Omega-6 fatty acids and inflammation [J]. Prostaglandins Leukot Essent Fatty Acids, 2018, 132: 41.

    [27] SAINI R K, KEUM Y S. Omega-3 and omega-6 polyunsaturated fatty acids: dietary sources, metabolism, and significance—a review [J]. Life Sci, 2018, 203: 255.

    [28] ZHOU B, LOU B, LIU J, et al. Serum metabolite profiles as potential biochemical markers in young adults with community-acquired pneumonia cured by moxifloxacin therapy [J]. Sci Rep, 2020, 10 (1): 4436.

    [29] CHEN L L, LI H K. Targeting microbiome: new opportunities and challenges in the study of pharmacodynamic mechanism of traditional Chinese medicine [J]. Shanghai Journal of Traditional Chinese Medicine, 2020, 54 (2): 15 (in Chinese).

    [30] IDDIR M, BRITO A, DINGEO G, et al. Strengthening the immune system and reducing inflammation and oxidative stress through diet and nutrition: considerations during the COVID-19 crisis [J]. Nutrients, 2020, 12 (6): E1562.

    [31] TAMBURINI S, CLEMENTE J C. Gut microbiota: neonatal gut microbiota induces lung immunity against pneumonia [J]. Nat Rev Gastroenterol Hepatol, 2017, 14 (5): 263.

    [32] WU T R, LIN C S, CHANG C J, et al. Gut commensal parabacteroides goldsteinii plays a predominant role in the anti-obesity effects of polysaccharides isolated from Hirsutella sinensis [J]. Gut, 2019, 68 (2): 248.

    [33] DANG A T, MARSLAND B J. Microbes, metabolites, and the gut-lung axis [J]. Mucosal Immunol, 2019, 12 (4): 843.

    [34] DHAR D, MOHANTY A. Gut microbiota and COVID-19 possible link and implications [J]. Virus Res, 2020, 285: 198018.

This Article

ISSN:1001-5302

CN: 11-2272/R

Vol 45, No. 15, Pages 3726-3739

August 2020

Downloads:0

Share
Article Outline

Abstract

  • 1 Materials
  • 2 Methods
  • 3 Results
  • 4 Discussion
  • References